Email Us Here

Inomagen Therapeutics Awarded $1.6 million NIH SBIR Phase 2 Grant to Develop Gene Therapy for Atrial Fibrillation

Proceeds from the award will be utilized to continue advancement of the company's novel gene therapy for the treatment of atrial fibrillation (AF), the world's most common arrythmia